Clinic study of Pranlukast capsule in treating bronchial asthma

Purpose: To compare the efficacy and safety of Pranlukast to Zafirlukast on asthmatic patients. Methods: To assess the asthmatic symptoms, pulmonary function, laboratory measurement and adverse effects of 225 patients after using study drug. Results: The average peak exporatory flow(PEF) in the morning and night improved significantly in two group patients after 1,2,3,4 weeks (P<0.001); forced exporatory volume in first second(FEV 1) improved significant in two group patients after 2,4 weeks (P<0.001);average asthmatic symptoms score in the morning and night decreased significantly after 4 weeks, the percent of symptomless days in the morning and night increased significantly in two group patients, the percent of symptomless all-days increase in two group patients, the puff number of using ventolin decreased in the morning and night in two group patients. The percent of days of no using ventolin all-days increase in two group patients. Conclusions: Pranlukast could improve the pulmonary function andsymptoms in asthma patients, and its adverse effect is light, it posses satisfactory clinic effect and safety.